Organisation paid for research Program year 2025 Source: CMS Open Payments

Complete Dermatology PLLC

Neither a doctor nor a teaching hospital

Research payments

$597,309

88 payments

Through program year 2025, Complete Dermatology PLLC is reported as receiving $597,309 in research payments, across 88 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $389,635 58
2024 Research $199,541 29
2023 Research $8,133 1

Breakdown

Who paid Research payments · program years 2023–2025
  1. Sanofi US Services Inc. $383,703 35 payments
  2. Pfizer Inc. $168,781 37 payments
  3. AbbVie, Inc. $44,824 16 payments
Studies the money was for Research payments · program years 2023–2025
  1. Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $166,482 12 payments
  2. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $164,452 14 payments
  3. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $156,781 36 payments
  4. Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) $39,862 8 payments
  5. A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $22,502 11 payments
  6. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $12,908 1 payment
  7. A Phase 2B Randomized Doubleblind 12Week Placebocontrolled Study With A 12Week Doubleblind Extension Period to Evaluate the Efficacy Safety and Tolerability of Ritlecitinib Pf06651600 in Adult Participants With Chronic Spontaneous Urticaria $12,000 1 payment
  8. A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis $10,579 1 payment
  9. A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis $6,745 1 payment
  10. A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata $1,836 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record